{"title":"用于阿尔茨海默病分级诊断的人工智能辅助多重荧光传感平台。","authors":"Yibiao Liu, Zhongzeng Zhou, Xingyun Liu, Jian Zeng, Qiong Liu, Tailin Xu","doi":"10.1039/d5tb01103e","DOIUrl":null,"url":null,"abstract":"<p><p>Blood-based biomarkers have become increasingly important for Alzheimer's disease (AD) diagnosis. However, due to individual variations, diagnostic accuracy using a single blood biomarker remains low, making it challenging to implement in large-scale AD screening efforts. Herein, we developed a multiplex fluorescent sensing platform for simultaneously measuring Aβ40, Aβ42, and P-tau181 in the blood, and constructed an artificial intelligence (AI) model. These three biomarkers were analyzed in 60 clinical samples: 15 healthy control, 15 subjective cognitive decline, 15 mild cognitive impairment, and 15 AD samples. The AI model based on these three biomarkers exhibited high predictive accuracy (91%), high positive predictive value (PPV) and low false rate (8.8%). The diagnostic accuracy and PPV of the AI model exceeded 90% for AD grading diagnosis in clinical samples. This study introduces a promising strategy for disease diagnosis and grading based on multi-biomarker analysis.</p>","PeriodicalId":94089,"journal":{"name":"Journal of materials chemistry. B","volume":" ","pages":""},"PeriodicalIF":5.7000,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"An AI-assisted multiplex fluorescence sensing platform for grading diagnosis of Alzheimer's disease.\",\"authors\":\"Yibiao Liu, Zhongzeng Zhou, Xingyun Liu, Jian Zeng, Qiong Liu, Tailin Xu\",\"doi\":\"10.1039/d5tb01103e\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Blood-based biomarkers have become increasingly important for Alzheimer's disease (AD) diagnosis. However, due to individual variations, diagnostic accuracy using a single blood biomarker remains low, making it challenging to implement in large-scale AD screening efforts. Herein, we developed a multiplex fluorescent sensing platform for simultaneously measuring Aβ40, Aβ42, and P-tau181 in the blood, and constructed an artificial intelligence (AI) model. These three biomarkers were analyzed in 60 clinical samples: 15 healthy control, 15 subjective cognitive decline, 15 mild cognitive impairment, and 15 AD samples. The AI model based on these three biomarkers exhibited high predictive accuracy (91%), high positive predictive value (PPV) and low false rate (8.8%). The diagnostic accuracy and PPV of the AI model exceeded 90% for AD grading diagnosis in clinical samples. This study introduces a promising strategy for disease diagnosis and grading based on multi-biomarker analysis.</p>\",\"PeriodicalId\":94089,\"journal\":{\"name\":\"Journal of materials chemistry. B\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.7000,\"publicationDate\":\"2025-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of materials chemistry. B\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1039/d5tb01103e\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of materials chemistry. B","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1039/d5tb01103e","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
An AI-assisted multiplex fluorescence sensing platform for grading diagnosis of Alzheimer's disease.
Blood-based biomarkers have become increasingly important for Alzheimer's disease (AD) diagnosis. However, due to individual variations, diagnostic accuracy using a single blood biomarker remains low, making it challenging to implement in large-scale AD screening efforts. Herein, we developed a multiplex fluorescent sensing platform for simultaneously measuring Aβ40, Aβ42, and P-tau181 in the blood, and constructed an artificial intelligence (AI) model. These three biomarkers were analyzed in 60 clinical samples: 15 healthy control, 15 subjective cognitive decline, 15 mild cognitive impairment, and 15 AD samples. The AI model based on these three biomarkers exhibited high predictive accuracy (91%), high positive predictive value (PPV) and low false rate (8.8%). The diagnostic accuracy and PPV of the AI model exceeded 90% for AD grading diagnosis in clinical samples. This study introduces a promising strategy for disease diagnosis and grading based on multi-biomarker analysis.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
